Latest & greatest articles for hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hepatitis

41. An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for treatment-naive chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resistance-associated substitut (Abstract)

An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for treatment-naive chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resistance-associated substitut A 12-week grazoprevir/elbasvir regimen is highly effective against hepatitis C virus genotype 1 (HCV-1) infection. The efficacy of an 8-week regimen for treatment-naive HCV-1-infected patients with mild fibrosis has not been

2019 EvidenceUpdates

42. Hepatitis E: symptoms, transmission, prevention, treatment

Hepatitis E: symptoms, transmission, prevention, treatment Hepatitis E: symptoms, transmission, treatment and prevention - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Hepatitis E: symptoms, transmission, treatment and prevention Updated 8 March 2019 Contents © Crown copyright 2019 This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view (...) this licence, visit or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: . Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned. This publication is available at https://www.gov.uk/government/publications/hepatitis-e-symptoms-transmission-prevention-treatment/hepatitis-e-symptoms-transmission-treatment-and-prevention Background Hepatitis E is an illness of the liver caused

2019 Public Health England

43. Hepatitis B vaccine for renal patients: patient group direction template

Hepatitis B vaccine for renal patients: patient group direction template application/vnd.openxmlformats-officedocument.wordprocessingml.document

2019 Public Health England

44. Frailty Associated With Waitlist Mortality Independent of Ascites and Hepatic Encephalopathy in a Multicenter Study (Abstract)

Frailty Associated With Waitlist Mortality Independent of Ascites and Hepatic Encephalopathy in a Multicenter Study Frailty is associated with mortality in patients with cirrhosis. We measured frailty using 3 simple tests and calculated Liver Frailty Index (LFI) scores for patients at multiple ambulatory centers. We investigated associations between LFI scores, ascites, and hepatic encephalopathy (HE) and mortality.Adults without hepatocellular carcinoma who were on the liver transplantation

2019 EvidenceUpdates

45. New Direct-acting Antiviral for Hepatitis C (Epclusa?

New Direct-acting Antiviral for Hepatitis C (Epclusa? MED CHECK April 2019/ Vol.5 No.13 · Page C N o 13 M ED HECK A p r i l 2 0 1 9 Accelerated Approval, Ignoring Harm, is a Crime New Direct-acting Antiviral for Hepatitis C (Epclusa ) Hemorrhage caused by an Anti-influenza Agent, Baloxavir Editorial Accelerated Approval, Ignoring Harm, is a Crime New Products New Direct-acting Antiviral for Hepatitis C (Epclusa ) Advance in hepatitis C with prior treatment failure or decompensated cirrhosis (...) for whom an anti-influenza drug should be effective. However, if you have severe flu symptoms, you may lose appetite and cannot eat. Then, you have to avoid using Xofluza due to the high risk of bleeding. After all, just like Tamiflu, Xofluza has no place in use for influenza infection. Accelerated approval, ignoring harm, is a crime.MED CHECK April 2019/ Vol.5 No.13 · Page New Direct-acting Antiviral for Hepatitis C ( Epclusa ) Advance in hepatitis C with prior treatment failure or decompensated

2019 Med Check - The Informed Prescriber

46. Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial. (Abstract)

Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial. Many people who inject drugs (PWID) are denied treatment for hepatitis C virus (HCV) infection, even if they are receiving opioid agonist therapy (OAT). Research suggests that HCV in PWID may be treated effectively, but optimal models of care for promoting adherence and sustained virologic response (SVR) have not been evaluated in the direct-acting antiviral (DAA

2019 Annals of Internal Medicine Controlled trial quality: predicted high

47. Radix Sophorae flavescentis versus no intervention or placebo for chronic hepatitis B. (Abstract)

Radix Sophorae flavescentis versus no intervention or placebo for chronic hepatitis B. Hepatitis B virus (HBV) infection, a liver disease caused by hepatitis B virus, may lead to serious complications such as cirrhosis and hepatocellular carcinoma. People with HBV infection may have co-infections including HIV and other hepatitis viruses (hepatitis C or D), and co-infection may increase the risk of all-cause mortality. Chronic HBV infection increases morbidity and psychological stress (...) and is an economic burden on people with chronic hepatitis B and their families. Radix Sophorae flavescentis, an herbal medicine, is administered most often in combination with other drugs or herbs. It is believed that it decreases discomfort and prevents replication of the virus in people with chronic hepatitis B. However, the benefits and harms of Radix Sophorae flavescentis for patient-centred outcomes are not known, and its wide usage has never been established with rigorous review methodology.To assess

2019 Cochrane

48. Effect of conversion from calcineurin inhibitors to everolimus on hepatitis C viremia in adult kidney transplant recipients. Full Text available with Trip Pro

Effect of conversion from calcineurin inhibitors to everolimus on hepatitis C viremia in adult kidney transplant recipients. Currently, there is no specific immunosuppressive protocol for hepatitis C (HCV)-positive renal transplants recipients. Thus, the aim of this study was to evaluate the conversion effect to everolimus (EVR) on HCV in adult kidney recipients.This is an exploratory single-center, prospective, randomized, open label controlled trial with renal allograft recipients with HCV

2019 Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia Controlled trial quality: uncertain

49. Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy (Abstract)

Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy To evaluate the safety and efficacy of IONIS-GCGRRx, a 2'-O-methoxyethyl antisense oligonucleotide targeting the glucagon receptor (GCGR), and the underlying mechanism of liver transaminase increases in patients with type 2 diabetes on stable metformin therapy.In three phase 2, randomized, double-blind (...) within the normal reference range at the 50-mg dose. There were no other significant safety observations and no symptomatic hypoglycemia or clinically relevant changes in blood pressure, LDL cholesterol, or other vital signs. At week 14, IONIS-GCGRRx 100 mg did not significantly affect mean hepatic glycogen content compared with placebo (15.1 vs. -20.2 mmol/L, respectively; P = 0.093) but significantly increased hepatic lipid content (4.2 vs. -2.7%, respectively; P = 0.005) in the presence

2019 EvidenceUpdates

50. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. (Abstract)

Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Although direct-acting antivirals have been used extensively to treat patients with chronic hepatitis C virus (HCV) infection, their clinical effectiveness has not been well reported. We compared the incidence of death, hepatocellular carcinoma, and decompensated cirrhosis between patients treated with direct-acting antivirals and those untreated, in the French ANRS CO22 (...) Hepather cohort.We did a prospective study in adult patients with chronic HCV infection enrolled from 32 expert hepatology centres in France. We excluded patients with chronic hepatitis B, those with a history of decompensated cirrhosis, hepatocellular carcinoma, or liver transplantation, and patients who were treated with interferon-ribavirin with or without first-generation protease inhibitors. Co-primary study outcomes were incidence of all-cause mortality, hepatocellular carcinoma

2019 Lancet

51. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Full Text available with Trip Pro

Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. The revolution in hepatitis C virus (HCV) treatment through the development of direct-acting antivirals (DAAs) has generated international interest in the global elimination of the disease as a public health threat. In 2017, this led WHO to establish elimination targets for 2030. We evaluated the impact of public health interventions on the global HCV epidemic and investigated whether WHO's

2019 Lancet

52. Chloroquine Is Effective for Maintenance of Remission in Autoimmune Hepatitis: Controlled, Double-Blind, Randomized Trial. Full Text available with Trip Pro

Chloroquine Is Effective for Maintenance of Remission in Autoimmune Hepatitis: Controlled, Double-Blind, Randomized Trial. Between 50% and 86% of patients with autoimmune hepatitis (AIH) relapse after immunosuppression withdrawal; long-term immunosuppression is associated with increased risk of neoplasias and infections. Chloroquine diphosphate (CQ) is an immunomodulatory drug that reduces the risk of flares in rheumatologic diseases. Our aims were to investigate the efficacy and safety of CQ

2019 Hepatology communications Controlled trial quality: predicted high

53. Public health guidance on HIV, hepatitis B and C testing in the EU/EEA

Public health guidance on HIV, hepatitis B and C testing in the EU/EEA SCIENTIFIC AD VICE www.ecdc.europa.eu Public health guidance on HIV, hepatitis B and C testing in the EU/EEA An integrated approachECDC SCIENTIFIC ADVICE Public health guidance on HIV, hepatitis B and C testing in the EU/EEA An integrated approach ii This guidance was commissioned by the European Centre for Disease Prevention and Control (ECDC), coordinated by Andrew J Amato-Gauci and Lara Tavoschi with the support of Helena (...) Kingdom Masoud Dara, World Health Organization (WHO) Regional Office for Europe, Denmark Michael Ninburg, World Hepatitis Alliance, United Kingdom Mika Salminen, National Institute for Health and Welfare, Finland Mojca Maticic, University Medical Centre Ljubljana, Slovenia Nikos Dedes, EATG/Positive Voice, Greece Peter Vickerman, University of Bristol, United Kingdom Philippa Easterbrook, WHO, Switzerland Raj Patel, IUSTI/NHS England, United Kingdom Ruta Kaupe, DIA+LOGS, Latvia Slim Fourati, European

2019 European Centre for Disease Prevention and Control - Public Health Guidance

54. Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA

Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA Suggested citation: European Centre for Disease Prevention and Control. Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA – An integrated approach. Stockholm: ECDC; 2018. Stockholm, December 2018 Reproduction is authorised, provided the source is acknowledged. PDF Print ISBN 978-92-9498-291-9 ISBN 978-92-9498-292-6 DOI 10.2900/809892 DOI 10.2900/579896 Catalogue number TQ-06-18-361-EN-N (...) Catalogue number TQ-06-18-361-EN-C © European Centre for Disease Prevention and Control, Stockholm, 2018 Scope and purpose of guidance The ECDC guidance on integrated testing of hepatitis B (HBV), hepatitis C (HCV) and HIV supports countries in the global effort to combat viral hepatitis and eliminate HIV as public health threats by 2030. At present, reaching and testing those at risk of infection with HIV, HBV or HCV is still a public health challenge across Europe. Figure 1. The case for integrated

2019 European Centre for Disease Prevention and Control - Public Health Guidance

55. Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes Full Text available with Trip Pro

Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes - GOV.UK GOV.UK uses cookies to make the site simpler. Search Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes Monitor glucose levels closely in patients with diabetes during direct-acting antiviral therapy for hepatitis C, particularly within the first (...) 3 months of treatment, and modify diabetes medication or doses when necessary. Patients with diabetes may experience symptomatic hypoglycaemia if diabetic treatment is continued at the same dose due to potential for an enhanced hypoglycaemic effect. Published 18 December 2018 From: Therapeutic area: , , Contents Advice for healthcare professionals: rapid reduction in hepatitis C viral load during direct-acting antiviral therapy for hepatitis C may lead to improvements in glucose metabolism

2019 MHRA Drug Safety Update

56. Hepatitis B Virus Infection in Pregnant Women: Screening

Hepatitis B Virus Infection in Pregnant Women: Screening Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation Pregnant women The USPSTF recommends screening for hepatitis B virus (HBV) infection in pregnant women at their first prenatal visit A View the Clinical Summary in Population Pregnant Persons Recommendation Screen for hepatitis B virus (HBV) infection. Grade: A Risk Assessment In the United States, new cases of HBV (...) test for detecting maternal HBV infection is the serologic identification of hepatitis B surface antigen (HBsAg). Screening should be performed in each pregnancy, regardless of previous HBV vaccination or previous negative HBsAg test results Screening Intervals A test for HBsAg should be ordered at the first prenatal visit. Women with unknown HBsAg status or with new or continuing risk factors for HBV infection (eg, injection drug use or a sexually transmitted infection) should be screened

2019 U.S. Preventive Services Task Force

57. AASLD?IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

AASLD?IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection - Ghany - 2020 - Hepatology - Wiley Online Library

2019 American Association for the Study of Liver Diseases

58. Drugs for hepatitis C: it's time to slash prices!

Drugs for hepatitis C: it's time to slash prices! Prescrire IN ENGLISH - Spotlight ''Drugs for hepatitis C: it's time to slash prices!'', 1 December 2018 {1} {1} {1} | | > > > Drugs for hepatitis C: it's time to slash prices! Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Drugs for hepatitis C: it's time to slash prices! The high prices (...) of hepatitis C drugs are an obstacle to treatment for most of the people around the world who are infected by the virus. When so-called direct-acting antiviral drugs against hepatitis C came onto the market around 2015, some stakeholders hailed them as a means of eradicating this disease. Sofosbuvir (Sovaldi°) was marketed in the United States at the exorbitant price of 1000 dollars per day, reflecting the company's strategy of seeking maximum profits in the richest countries and not eradication

2018 Prescrire

59. Chronic hepatitis B virus infection. (Abstract)

Chronic hepatitis B virus infection. Chronic hepatitis B virus infection is a global public health threat that causes considerable liver-related morbidity and mortality. It is acquired at birth or later via person-to-person transmission. Vaccination effectively prevents infection and chronic hepatitis B virus carriage. In chronically infected patients, an elevated serum hepatitis B virus DNA concentration is the main risk factor for disease progression, although there are other clinical (...) . With current vaccines, therapies, and an emphasis on improving linkage to care, WHO's goal of eliminating hepatitis B virus as a global health threat by 2030 is achievable.Copyright © 2018 World Health Organization. Published by Elsevier Ltd. All rights reserved. Published by Elsevier Ltd.. All rights reserved.

2018 Lancet

60. Sofosbuvir (hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V

Sofosbuvir (hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Sofosbuvir (chronische Hepatitis C bei Jugendlichen) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11 January 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A17-55 Sofosbuvir (chronic hepatitis C in adolescents) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-55 Version 1.0 Sofosbuvir (chronic hepatitis C in adolescents) 11 January 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sofosbuvir (chronic hepatitis C in adolescents) – Benefit assessment according to §35a Social Code Book V

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)